查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197291

吸入一氧化氮市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Inhaled Nitric Oxide Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，可吸入一氧化氮市場預計將以 4.6% 左右的複合年增長率增長。

主要亮點

  • 推動市場增長的某些因素包括呼吸道疾病和其他相關疾病的患病率上升以及持續的研發活動。
  • 吸入的一氧化氮 (iNO) 是一種肺血管擴張劑，在調節血管肌張力方面起著重要作用。 自從上個世紀認識到一氧化氮 (NO) 是一種重要的內皮衍生血管擴張劑分子以來，NO 研究領域已經擴展到包括生物醫學研究的多個領域。 現在眾所周知，NO 是體內的重要信使。
  • 最近的數據表明，吸入一氧化氮可能適用於多種疾病。 例如，研究表明吸入 NO 是一種安全有效的試劑，可用於測量肺血管床的血管舒張能力。
  • 目前的證據還表明，iNO 可改善妊娠 35 週以上的嬰兒的氧氣輸送並減少死亡或出生時需要體外膜氧合的綜合結果。 由於這些因素，市場有望在預測期內實現穩定增長。

吸入一氧化氮市場趨勢

哮喘和慢性阻塞性肺病在吸入一氧化氮市場表現出良好的增長

美國過敏、哮喘和免疫學協會 (AAAI) 表示，2016 年，美國約有 8.3% 的兒童被發現患有哮喘。 發現 9.2% 的男孩和 7.4% 的女孩患哮喘病的可能性略高於女孩。

兒童哮喘患病率從 2001 年的 8.7% 上升到 2010 年的 9.4%，然後下降到 2016 年的 8.3%。 儘管並非所有變化都具有統計學意義，但亞人口統計研究表明，墨西哥/墨西哥裔美國兒童除外，他們的哮喘患病率從 2001 年的 5.1% 增加到 2016 年的 6.5% 在該群體中觀察到類似的概況。

根據疾病預防控制中心的數據，從 2013 年到 2017 年，美國 18 歲及以上從不吸煙的工作成年人中估計有 240 萬 (2.2%) 患有慢性阻塞性肺病。 在從不吸煙者中，COPD 患病率最高的是信息行業 (3.3%)、採礦業 (3.1%) 以及辦公室和行政支持人員 (3.3%)。 女性的 COPD 患病率高於男性。

此外，根據慢性阻塞性肺疾病全球倡議（GOLD）發布的2019年報告，全球有6500萬人患有慢性阻塞性肺疾病（COPD），每年有300萬人死亡，位居第三。死亡原因。

北美主導吸入一氧化氮市場

根據 Matthew Diamond 於 2020 年發表的一篇文章，美國 ARDS 的估計發病率為 64.2-78.9 例/100,000 人年。 25% 的 ARDS 病例最初被歸類為輕度，75% 的病例被歸類為中度或重度。 然而，三分之一的輕度疾病患者會發展為中度或重度疾病。

哮喘的患病率在醫療保健和社會援助行業的工人中也最高，8.8% 的工人在調查時報告患有哮喘。

此外，教育服務業以8.2%的比例位居第二。 因此，預計在預測期內，呼吸系統疾病患病率的增加將有助於北美佔據較大的市場份額。

吸入式一氧化氮市場競爭對手分析

市場競爭激烈，參與者眾多。 2020 年 2 月，Bellerophon Therapeutics 公佈了其用於治療肺纖維化相關肺動脈高壓（PH-PF）的 INOpulse（脈衝吸入一氧化氮）遞送系統的 2b 期研究的陽性頂線數據。宣布。 Air Liquide Healthcare、Mallinckrodt、Matheson Tri-Gas、Merck KGaA、Novotelis、NuMed Plus、Perma Pure LLC 和 Praxair Technology 等公司佔據了很大的市場份額。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 調查結果
  • 調查假設
  • 本次調查的範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 呼吸道疾病和其他相關疾病的患病率上升
    • 正在進行的研究和開發活動
  • 市場製約因素
    • 每個地區都有嚴格的應用標準
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按產品類型
    • 煤氣
    • 交付系統
  • 通過申請
    • 新生兒呼吸治療
    • 支氣管哮喘/COPD
    • 急性呼吸窘迫綜合徵
    • 瘧疾藥物
    • 肺結核治療
    • 其他用途
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Air Liquide Healthcare
    • Mallinckrodt
    • Matheson Tri-Gas Inc.
    • Merck KGaA
    • Novoteris
    • Nu-Med Plus
    • Perma Pure LLC
    • Praxair Technology Inc.

第7章 市場機會今後動向

簡介目錄
Product Code: 68861

The inhaled nitric oxide market is anticipated to register a CAGR of nearly 4.6%, during the forecast period.

Key Highlights

  • Certain factors that are driving the market growth include rising prevalence of respiratory and other associated diseases and ongoing research and development activities.
  • Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating vascular muscle tone. Since the acknowledgment of nitric oxide (NO) as a key endothelial-derived vasodilator molecule in the last century, the field of NO research has expanded to encompass several areas of biomedical research. At present, it is well established that NO is an important signaling molecule throughout the body.
  • Recent data suggest that inhaled NO can be applied in a wide variety of diseases. For instance, studies indicate that inhaled NO is a safe and effective agent to determine the vasodilatory capacity of the pulmonary vascular bed.
  • Current evidence also shows that iNO improves oxygenation and decreases the combined outcome of death or necessity for extracorporeal membrane oxygenation in infants of more than 35 weeks' gestational age at birth. Owing to all the aforementioned factors, the market is expected to observe steady growth over the forecast period.

Inhaled Nitric Oxide Market Trends

Asthma and COPD Shows Lucrative Growth in the Inhaled Nitric Oxide Market

* The American Academy of Allergy Asthma and Immunology (AAAI) states that, in 2016, approximately 8.3% of children in the United States was found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively.

* Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010, and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among subdemographic groups studied, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016.

* According to the CDC, during 2013-2017, an estimated 2.4 million (2.2%) US working adults aged more than 18 years who never smoked had COPD. The highest COPD prevalences among persons who never smoked were in the information (3.3%) and mining (3.1%) industries and office and administrative support occupation workers (3.3%). Women had higher COPD prevalences than did men.

* Moreover, as per the 2019 report published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide.

North America Dominates the Inhaled Nitric Oxide Market

* According to a 2020 article by Matthew Diamond, estimates of the incidence of ARDS in the United States range from 64.2 to 78.9 cases/100,000 person-years. 25% of ARDS cases are initially classified as mild and 75% as moderate or severe. However, a third of the mild cases go on to progress to moderate or severe disease.

* In addition, asthma prevalence was highest among workers in the healthcare and social assistance industry, with 8.8% of workers stating that they had asthma at the time of the survey.

* The source also states that participants in the educational services industry reported the second-highest rate of asthma at 8.2%. Hence, the growing prevalence of respiratory diseases is expected to contribute to the significant market share of North America over the forecast period.

Inhaled Nitric Oxide Market Competitor Analysis

The market is competitive and consists of a number of players. In February 2020, Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF). Companies like Air Liquide Healthcare, Mallinckrodt, Matheson Tri-Gas Inc., Merck KGaA, Novoteris, Nu-Med Plus, Perma Pure LLC, Praxair Technology Inc., hold the substantial market share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Respiratory and Other Associated Diseases
    • 4.2.2 Ongoing Research and Development Activities
  • 4.3 Market Restraints
    • 4.3.1 Strict Apllication Norms across Various Regions
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Gas
    • 5.1.2 Delivery Systems
  • 5.2 By Application
    • 5.2.1 Neonatal Respiratory Treatment
    • 5.2.2 Asthma and COPD
    • 5.2.3 Acute Respiratory Distress Syndrome
    • 5.2.4 Malaria Treatment
    • 5.2.5 Tuberculosis Treatment
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Air Liquide Healthcare
    • 6.1.2 Mallinckrodt
    • 6.1.3 Matheson Tri-Gas Inc.
    • 6.1.4 Merck KGaA
    • 6.1.5 Novoteris
    • 6.1.6 Nu-Med Plus
    • 6.1.7 Perma Pure LLC
    • 6.1.8 Praxair Technology Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS